Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Selectis Health (GBCS) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Selectis Health (GBCS) over the last 14 years, with Q3 2025 value amounting to 0.62%.

  • Selectis Health's EBITDA Margin rose 85900.0% to 0.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.42%, marking a year-over-year increase of 99900.0%. This contributed to the annual value of 6.91% for FY2024, which is 129200.0% up from last year.
  • Per Selectis Health's latest filing, its EBITDA Margin stood at 0.62% for Q3 2025, which was up 85900.0% from 0.84% recorded in Q2 2025.
  • Over the past 5 years, Selectis Health's EBITDA Margin peaked at 24.78% during Q1 2021, and registered a low of 27.84% during Q4 2023.
  • Moreover, its 5-year median value for EBITDA Margin was 0.94% (2024), whereas its average is 2.93%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by -395800bps in 2021, then surged by 269100bps in 2024.
  • Selectis Health's EBITDA Margin (Quarter) stood at 7.02% in 2021, then crashed by -30bps to 9.15% in 2022, then crashed by -204bps to 27.84% in 2023, then skyrocketed by 97bps to 0.94% in 2024, then soared by 167bps to 0.62% in 2025.
  • Its EBITDA Margin was 0.62% in Q3 2025, compared to 0.84% in Q2 2025 and 0.56% in Q1 2025.